Lv41
510 积分 2026-05-19 加入
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
1小时前
已完结
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2小时前
已完结
Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against monkeypox virus
1个月前
已完结
皖公网安备34019202002308
